A. Yamamichi

This study shows that pretreating CAR-T cells with Metformin and Rapamycin improves their metabolic function and anti-glioma activity under hypoxic conditions in brain tumors.

The paper identifies tumor-specific alternative splicing events in glioma that could generate cell-surface antigens but finds significant spatiotemporal heterogeneity and lack of proteomic evidence.

The paper identifies tumor-wide splicing aberrations that generate public neoantigens, enabling T-cell-based immunotherapies targeting intratumoral heterogeneity.

This study shows that glioma-induced neuronal circuit remodeling creates regional immunosuppression in glioblastomas by altering tumor-associated macrophages and T-cell infiltration.

This paper develops a novel transgenic mouse model expressing EGFRvIII-CAR on T-cells to study CAR T-cell therapy in syngeneic glioblastoma models.